Widely used:Recently Viewed
Clear AllQuality Score 
0/0
Growth Score
0/0
Valuation Score
0/0
Momentum Score
0/0
Today’s Range
52 Week Range
Liquidity
Market cap
$49 Mln
P/E Ratio
--
P/B Ratio
11.34
Industry P/E
--
Debt to Equity
0.18
ROE
-1.89 %
ROCE
-181.03 %
Div. Yield
0 %
Book Value
0.08
EPS
-0.42
CFO
CA$-190.21 Mln
EBITDA
CA$-202.28 Mln
Net Profit
CA$-224.13 Mln
|
YTD
|
1 Month
|
3 Months
|
1 Year
|
3 Years
|
5 Years
|
10 Years
|
|
|---|---|---|---|---|---|---|---|
|
Oncolytics Biotech - ADR
| -39.13 | -11.62 | -29.36 | -47.53 | -25.59 | -16.13 | -22.51 |
|
BSE Sensex
| 1.23 | 1.57 | 3.97 | 7.26 | 11.47 | 20.39 | 11.18 |
|
S&P Small-Cap 600#
| -5.82 | -5.34 | -13.73 | -6.30 | 5.30 | 2.98 | 5.53 |
|
2023
|
2022
|
2021
|
2020
|
2019
|
2018
|
2017
|
|
|---|---|---|---|---|---|---|---|
|
Oncolytics Biotech - ADR
| -17.18 | 17.27 | -41.60 | -50.00 | 162.98 | -66.26 | 173.52 |
|
S&P Small-Cap 600
| 13.89 | -17.42 | 25.27 | 9.57 | 20.86 | -9.70 | 11.73 |
|
BSE Sensex
| 18.74 | 4.44 | 21.99 | 15.75 | 14.38 | 5.87 | 27.91 |
Is there a threat to the company's solvency?
Can creative accounting be detected through the financial numbers?
How did the company perform in the last one year?
3Y Avg -- 5Y Avg -- TTM --
P/E Ratio
--
--Min --Median --Max
P/B Ratio
--
--Min --Median --Max
Earnings Yield (%)
--
Earnings Yield (%) = EBIT / Enterprise value
PEG Ratio
--
Price = Price / Earnings to growth ratio
Oncolytics Biotech Inc., a clinical-stage biopharmaceutical company, engages in the research, development, and commercialization of oncology treatments. The company develops pelareorep, an intravenously delivered immunotherapeutic agent for the... treatment of hormone receptor-positive / human epidermal growth factor 2-negative advanced and metastatic breast cancer, metastatic pancreatic ductal adenocarcinoma, and anal cancer. It has an agreement with Roche Holding AG to supply its immune checkpoint inhibitors, atezolizumab, for use in its ongoing sponsored studies. Oncolytics Biotech Inc. was incorporated in 1998 and is headquartered in Calgary, Canada. Address: 322 11th Avenue SW, Calgary, AB, Canada, T2R 0C5 Read more
President, CEO & Director
Dr. Matthew C. Coffey M.B.A., Ph.D.
President, CEO & Director
Dr. Matthew C. Coffey M.B.A., Ph.D.
Headquarters
Calgary, AB
Website
Our rating system has guided millions of investors in the past 20 years.
The total asset value of Oncolytics Biotech Inc - ADR stood at $ 20 Mln as on 31-Dec-24
The share price of Oncolytics Biotech Inc - ADR is $0.56 (NASDAQ) as of 25-Apr-2025 16:00 EDT. Oncolytics Biotech Inc - ADR has given a return of -25.59% in the last 3 years.
Oncolytics Biotech Inc - ADR has a market capitalisation of $ 49 Mln as on 21-Apr-2025. As per Value Research classification, it is a Small Cap company.
Since, TTM earnings of Oncolytics Biotech Inc - ADR is negative, P/E ratio is not available.
Step 1. Open a demat account through a broker. You would need to provide your email, PAN, bank account details, aadhar details, etc., for KYC
Step 2. Sign in to the broker’s application through a mobile app or website. Use the Login ID and password provided by your broker.
Step 3. Transfer funds from your bank account into the wallet present in your brokerage account.
Step 4. Search for the Oncolytics Biotech Inc - ADR and enter the required number of quantities and click on buy to purchase the shares of Oncolytics Biotech Inc - ADR.
Oncolytics Biotech Inc., a clinical-stage biopharmaceutical company, engages in the research, development, and commercialization of oncology treatments. The company develops pelareorep, an intravenously delivered immunotherapeutic agent for the treatment of hormone receptor-positive / human epidermal growth factor 2-negative advanced and metastatic breast cancer, metastatic pancreatic ductal adenocarcinoma, and anal cancer. It has an agreement with Roche Holding AG to supply its immune checkpoint inhibitors, atezolizumab, for use in its ongoing sponsored studies. Oncolytics Biotech Inc. was incorporated in 1998 and is headquartered in Calgary, Canada. Address: 322 11th Avenue SW, Calgary, AB, Canada, T2R 0C5
The CEO & director of Dr. Matthew C. Coffey M.B.A., Ph.D.. is Oncolytics Biotech Inc - ADR, and CFO & Sr. VP is Dr. Matthew C. Coffey M.B.A., Ph.D..
There is no promoter pledging in Oncolytics Biotech Inc - ADR.
Some of the close peers are:
| Company | Market Cap($ Mln) |
|---|
| Oncolytics Biotech Inc. - ADR | Ratios |
|---|---|
|
Return on equity(%)
|
-189.05
|
|
Operating margin(%)
|
--
|
|
Net Margin(%)
|
--
|
|
Dividend yield(%)
|
--
|
No, TTM profit after tax of Oncolytics Biotech Inc - ADR was $0 Mln.
$-0.03
(
